

Diagnosis of COVID-19 associated arthritis in patients with or without underlying rheumatic and musculoskeletal disease (RMD) supported by musculoskeletal ultrasound: a case series from three European centres

D. Vogler¹, P. Ruscitti², L. Navarini³, R. Giacomelli⁴, A. Iagnocco⁵, P. Hoff¹, G.-R. Burmester¹, S. Ohrndorf¹

Supplementary file

Supplementary Table S1. (extended version)

Case, Age (years)/ Sex (♀, ♂)	RMDs	Comorbidities (non-RMDs)	COVID-19 diagnosis	Severity of illness	Onset of arthritis after COVID-19 diagnosis	Affected joints	Activity score	Laboratory findings	Treatment arthritis	Outcome	Additions
Case 1 , 53/♂	PsA, PA subset (DAPSA 11.3 under SSZ), Chondrocalcinosis		10/20 RT-PCR	Mild-moderate	3 days	Right MCP2, right PIP3, left wrist	DAPSA 15.1	CRP: 11.0 mg/l	Restart SSZ, switch to ADA	Low disease activity after switch to ADA	DMARD paused during COVID-19
Case 2 , 58/♀	RA (CDAI 5 under MTX + Abatacept)		11/20 RT-PCR	Mild	7 days	Right and left wrists, right MCP2-4, right PIP2, left MCP2-4, left PIP3	CDAI 26.5		Restart MTX + Abatacept	Low disease activity	DMARD paused during COVID-19
Case 3 , 83/♂		Hypertension	02/21 RT-PCR	Severe	5 days	Right MCP5	VAS 60/100	CRP: 93.6 mg/l ESR: 57 mm/h	GC	Recovery	GC in the context of COVID-19
Case 4 , 72/♀		IDA, Dyslipidaemia	03/21 RT-PCR	Severe	Concomitant	Right and left wrists, right and left knee joints, right and left shoulders, right MCP1-3, left MCP1, right and left IP1	VAS 80/100	CRP: 53.2 mg/l	GC	Recovery	GC in the context of COVID-19
Case 5 , 61/♂	RA (in remission under MTX + Sarilumab)		03/21 RT-PCR	Mild	3 days	Right wrist, right MCP3+4, right PIP2+3, left MCP4, left PIP2, right and left knee joints	CDAI 28 SDAI 30.4	CRP: 24.0 mg/l	Restart MTX + Sarilumab	Persistent activity (CDAI 24), therapeutic change intended	DMARD paused during COVID-19
Case 6 , 60/♂		Tick bite (many years ago), Dyslipidemia	03/20 RT-PCR	Moderate	16 weeks	MST: 30-60 min, arthralgia: right and left shoulder/knee joints, right MCP3, left MCP1; subjective swelling of finger/knee joints	VAS 50/100 DAS28 4.2	CRP: 2.6 mg/l ESR: 20 mm/h RF: neg. ACPA: neg. ANA: 1:640 HLA-B27: neg.	NSAID, GC, MTX	LORA in remission	

Case 7 , 53/♀	Localized NSCLC in remission after lobectomy, history of Enchondroma of the left upper arm	11/20 Serology	Mild	8 weeks	MST: 60 min, arthralgia: right and left hip joints, right and left knee joints, right ankle joint; subjective swelling of the left knee TJC 0/28, SJC 0/28 (+ tender swelling of the right ankle)	VAS 50/100	CRP: 1.1 mg/l ESR: 2 mm/h RF: pos. ACPA: neg. ANA: neg. HLA-B27: neg	NSAID, GC, SSZ, GC infiltration	Relapse, prolonged course	Vaccination (Comirnaty®) 9 days before symptom onset
Case 8 , 42/♀	Migraine, history of Scleritis	12/20 RT-PCR	Mild	4 weeks	MST: 24 h, subjective symmetrical swelling of the wrists, finger joints, knee/ankle joints TJC 8/28 (right and left wrists, left MCP4, left PIP3+4, right PIP2-4), SJC 3/28 (right and left wrists, left MCP2, + right and left ankle joints)	VAS 60/100	CRP: 1.1 mg/l ESR: 9 mm/h RF: neg. ACPA: marginal pos. (22.8 U/ml) ANA: neg.	NSAID, GC	Recovery	Concomitant symptoms: night sweat, fatigue; serology: no signs of an acute Parvovirus B19 infection
Case 9 , 51/♀	Trigger finger D4 right hand, history of giant-cell tumor of the distal phalanx D2 right hand	12/20 RT-PCR	Mild	12 weeks	TJC 2/28 (right and left wrists) SJC 0/28		CRP: 0.7 mg/l ESR: 13 mm/h RF: marginal pos. (20.4 U/ml) ANA: 1:160	NSAID	Recovery	NXP2-antibody pos.
Case 10 , 69/♂	Hypertension, BPH, MGUS	12/20 RT-PCR	Mild	6 weeks	Arthralgia: right wrist, right MCPs; subjective swelling right wrist, right MCPs, right PIPs		CRP: 1.8 mg/l ESR: 20 mm/h RF: pos. (RF IgA: 156.5 U/ml, RF IgM: 86.0 U/ml) ACPA: neg. ANA: 1:2560	MTX	RA in remission	

ACPA: anti-citrullinated protein antibody; ADA: adalimumab; ANA: antinuclear antibody; AZA: azathioprine; BPH: benign prostatic hyperplasia; CD4I: Clinical Disease Activity Index for RA; CRP: C-reactive protein; D: digit; DAPSA: Disease Activity Index For Psoriatic Arthritis; DAS28: Disease Activity Score 28; DMARD: disease-modifying anti-rheumatic drug; ESR: erythrocyte sedimentation rate; GC: glucocorticoid; HLA-B27: human leukocyte antigen-B27; IDA: iron deficiency anemia; LORA: late-onset rheumatoid arthritis; MCP: metacarpophalangeal joint; MGUS: monoclonal gammopathy of undetermined significance; MST: morning stiffness; MTX: methotrexate; neg.: negative; NSCLC: non-small cell lung carcinoma; NXP2: nuclear matrix protein 2; PA: polyarticular; RT-PCR: reverse transcription polymerase chain reaction; pos.: positive; PIP: proximal interphalangeal joint; PsA: psoriatic arthritis; pSS: primary Sjögren's syndrome; RA: rheumatoid arthritis; RF: rheumatoid factor; RMD: rheumatic and musculoskeletal disease; SCL: swollen joint count; SSZ: sulfasalazine; TJC: tender joint count; VAS: visual analogue scale.